综合收入同比下滑24.8%,和黄医药的“创新药大树”究竟长成了吗?

医药研究社
20 Mar

做纯粹的创新药企。来源|医药研究社经过多年的“左右互搏”,和黄医药发展的天平明显偏向创新药资产了。据和黄医药3月19日发布的最新财报,2024年,公司实现综合收入6.302亿美元,同比下滑24.8%;应占净收益3772.9万美元,同比减少62.56%;每股普通股盈利0.04美元。整体呈现出下滑态势,但其中也有强劲的增长力显露,主要集中于肿瘤业务。财报显示,2024年,和黄医药肿瘤产品市场销售额增长...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10